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poor adherence to diabetes medications (Morisky adherence score < 6). The propor-
tion of individuals with poor adherence rather than good adherence, was higher 
among individuals with high B-IPQ scores for illness consequences (65%, p < 0.006), 
illness symptoms (67%, p < 0.008), emotional effect of illness (63%, p < 0.012) and 
among those with low B-IPQ scores for illness understanding (76%, p < 0.008). Illness 
beliefs regarding how well treatment can control diabetes (0.23, p < 0.007), concerns 
about diabetes (0.21, p < 0.017) and understanding of the illness (0.20, p < 0.002), 
had positive correlations with medication adherence. CONCLUSIONS: Illness beliefs 
were associated with adherence to diabetes medication and may be useful in assessing 
patients’ potential for adherence problems.
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RELEASE GLIPIZIDE FOR TYPE 2 DIABETES MELLITUS: A SYSTEMATIC 
REVIEW
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OBJECTIVES: Compliance with treatment is a key factor for successful treatment of 
chronic conditions like type 2 diabetes mellitus. Once-daily extended-release glipizide 
(GXL) has been showing more appealing in patient compliance. However, the data 
on comparison of GXL with other oral glucose-lowering drugs concerning compliance 
is limited. We tried to assess the compliance to GXL treatment for type 2 diabetes 
mellitus when compared with immediate-release glipizide(GIR). METHODS: We 
searched Medline, EMBASE, Cochrane Library, and the Chinese Biomedical database 
from their inception to end-Dec. 2009, as well as traced the reference lists. Rand-
omized or non-randomized studies that reported medication compliance/adherence or 
persistence when using GXL versus GIR for treating the type 2 diabetes mellitus were 
included. Four reviewers judged trial eligibility and extracted data independently. We 
pooled trial data using the random-effect model and explored heterogeneity by using 
pre-speciﬁed variables. RESULTS: A total of 9 published studies (n = 13 512) were 
included. GXL resulted in a 7% increase in compliance when compared with GIR 
(RD = 0.07, 95%CI = 0.06 to 0.08). The subgroup analyses showed that GXL 
increased patient compliance by 7% when compared with GIR in 4 retrospective 
database analyses (n = 13 250, RD = 0.07, 95%CI = 0.05 to 0.10) and showed no 
difference in 5 randomized trials (n = 262, RD = 0.01, 95%CI = −0.03 to 0.05). There 
was no signiﬁcant difference in patient compliance between ﬁxed-dose GXL and GIR 
(RD = 0.05, 95%CI = −0.01 to 0.11); however, the titrated-dose GXL signiﬁcantly 
increased patient compliance by 6% (RD = 0.06, 95%CI = 0.03 to 0.09). When 
compared to GIR, GXL in long-term treatments (equal to or more than 1 year) 
increased patient compliance by 7% (RD = 0.07, 95%CI = 0.05 to 0.08), while no 
signiﬁcant difference in short-term treatments (less than 1 year). CONCLUSIONS: 
When compared to immediate-release glipizide, extended-release glipizide could 
increase long-term patient compliance in retrospective database studies, while the 
increase in the short-term compliance to GXL was not observed.
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OBJECTIVES: The aim of this study was to measure adherence and persistence of 
oral hypoglycemic agents among Type II Diabetes patients and to examine differences 
in adherence and persistence by type of oral hypoglycemic agent (OHA) and demo-
graphic characteristics. METHODS: A retrospective analysis was conducted using 
Mississippi Medicaid claims data for 2002 through 2004. After a 6-month wash-out 
period, patients beginning OHA monotherapy were classiﬁed as taking sulfonylurea, 
metformin hydrochloride, thiazolidinediones (TZDs) or other. Patients were observed 
until they had a lapse in Medicaid coverage or discontinued mono therapy on the 
original OHA. A reﬁll gap > 2*day supply was considered to be discontinuation of 
therapy. Persistence was measured as percent of patients remaining on therapy at the 
end of each month. Adherence rates, proportion of days covered (PDC), were com-
puted for each 90 day period that patients remained on therapy after the ﬁrst ﬁll date. 
RESULTS: A total of 6,206 diabetic patients > 18 years of age were included with 
49% on sulfonylurea, 29% on metformin and 16% on TZDs. After 6 months persist-
ence was signiﬁcantly higher for sulfonylurea and TZD (46% and 45% at 12 months) 
compared to metformin (42%). Persistence dropped to around 25% by 18 months. 
Mean adherence rates for Q1 (ﬁrst 90-day period) were 80% for metformin, 82% for 
sulfonylurea, and 85% for TZD. Mean adherence rates dropped in Q2 to 68% for 
metformin, 71% for sulfonylurea, and 72% for TZD and remained relatively stable 
for patients remaining on therapy for up to 2 years. CONCLUSIONS: The rapid drop 
in persistency for monotherapy OHAs is not surprising since diabetic regimens are 
frequently modiﬁed. Although average adherence rates for all types of monotherapy 
OHAs remained steady after Q2, the average rate was below 80%. These results 
indicate that new OHA patients need extra counseling about the importance of 
adherence.
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OBJECTIVES: Oral antidiabetics(OAD) have comparable safety and efﬁcacy in ﬁxed-
dose combination therapies(FDCT) and loose-pill combination therapies(LPCT) for 
patients with Diabetes Mellitus Type II(T2DM). To evaluate FDCT outcomes besides 
safety and efﬁcacy a systematic review was conducted. METHODS: Searches of 
Medline/Embase databases from 1998–2009 used predeﬁned search terms: “ﬁxed-dose 
combination”, “loose-dose combination” and “diabetes”. Additionally, we reviewed 
abstracts from ISPOR, EASD and ADA meetings. T2DM studies were included if they 
reported adherence, patient reported outcomes(PRO), costs, resource use or cost-
effectiveness. RESULTS: Seventeen studies met the search criteria. Seven studies 
reported adherence. Adherence was 10–13% higher for FDCT than LPCT in patients 
starting combination therapy(two studies). Adherence decreased 1.5% and 10.0% 
when switching from monotherapy to combination therapy for FDCT and LPCT, 
respectively(one study, P < 0.001). Three studies report adherence when switching 
from LPCT to FDCT versus remaining on LPCT. Switching to FDCT increased adher-
ence 3.5%–12.4%, while remaining on LPCT changed adherence −1.5% to 5.0%(P 
< 0.005). For patients newly initiating OAD medication, one study found no adherence 
advantage for FDCT, compared with monotherapy or LPCT. Five randomized con-
trolled trials(RCTs) reported treatment satisfaction. Four publications found patients 
preferred FDCT using the Diabetes Treatment Satisfaction Questionnaire(DTSQ). One 
publication found improved satisfaction for one DTSQ subscale only. Five abstracts 
reported economic outcomes. Two abstracts determined patients on FDCT use fewer 
health care resources and decreased direct health care costs by $169 and $255 patient 
per month than LPCT(P < 0.05). Two cost effectiveness models determined clinical 
beneﬁts from clinical trials translate into cost savings and increased life expectancy. 
One budget impact model reported minimal budget impact. CONCLUSIONS: Com-
pared to T2DM patients on LPCT, FDCT users may have better adherence, improved 
satisfaction, and lower direct medical costs. Overall, data for economic implications 
are limited. Further studies are warranted to further deﬁne potential beneﬁt of FDCT 
in T2DM, a prevalent and costly disease.
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OBJECTIVES: The objective of this research project was to evaluate the effect of 
health insurance plan type on anti-diabetic medication adherence as measured by 
medication possession ratios (MPR > 0.80: good MPR) for oral medications. 
METHODS: The data source for this research project was the 2000–2001 MarketScan 
dataset, which is comprised of administrative claims data for over 2.5 million privately 
insured individuals in the United States. MPR was deﬁned as the sum of days 
supply each anti-diabetic medication divided by the number of days between the ﬁrst 
and last prescription ﬁll dates plus the number of days for the last reﬁll. RESULTS: 
The odds of having a good MPR for oral anti-diabetic medications were evaluated 
using multiple logistic regression models controlled for insurance plan type plus 
demographic and clinical characteristics of the target patient population. A propensity 
score analysis was done using a stratiﬁcation approach to further control for selection 
bias. The proportion of patients with MPR ≥80% was 68.2%. CONCLUSIONS: 
Patients in capitated plans were more likely to have good MPR compared to FFS, PPO 
and POS plan types (odds ratios: 0.75, p < 0.001; 0.81, p < 0.001; 0.81, p < 0.001, 
respectively). This relationship remained in all quintiles of the propensity score 
analysis.
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OBJECTIVES: 1. To determine the pattern of adherence to statins among the diabetes 
patients at a self-insured university. 2. To determine the effect of independent variables 
[age, gender, co-payment, and campus location (main campus/health science campus)] 
on adherence to statins. METHODS: Pharmacy claims data was used to identify 
patients using both diabetes and statin drugs during the study period between January 
1, 2006 and June 2, 2008. Adherence to statins was calculated at regular observation 
periods using Medication possession ratio (MPR). Patients with MPR ≥ 80% were 
considered adherent. Patients with MPR < 80% were considered non-adherent. Logis-
tic regression was used to study the effect of independent variables on adherence to 
statins. RESULTS: Two hundred and ninety-ﬁve patients were included in the study. 
The mean age of the patients was 55.09 ± 9.30 years. The mean MPR of statins was 
0.76, 0.70, and 0.68 in the 6, 12, and 24 months observation periods respectively. 
During the ﬁrst six months, about 58% of patients were adherent to statins with MPR 
≥ 0.80. About 51% and 48% of patients were adherent to statins during the 12 and 
24 months observation periods. Age was signiﬁcantly positively associated with adher-
ence to statins (Odds ratio, 1.04; 95% CI, 1.01–1.07). Males were 48.3% more likely 
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to be adherent than females (p = 0.05). CONCLUSIONS: American Diabetes Associa-
tion guidelines recommend statin therapy in every diabetes patients of age 40 years 
and above, regardless of their low-density lipoprotein level. Low adherence can result 
in the development of cardiovascular diseases, which can lead to increase in outpatient 
and emergency room visits and hence, increase in the health care costs. Adherence to 
statins was suboptimal among this study population. This presents an increased risk 
of developing cardiovascular diseases, which can lead to increases in the health care 
costs for this self-insured university.
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OBJECTIVES: To examine the effect of a community pharmacy based medication 
therapy management program (MTM) on patient outcomes over one year. METHODS: 
A one year, pre-post longitudinal study. Patients served as their own controls. Com-
munity pharmacists provided MTM services to the City of Toledo employees and their 
dependents with diabetes. Employees were seen every 3 months at one of seven par-
ticipating pharmacy sites. Participants received a 3 month supply of medications at 
the cost of one co-pay as an incentive. Data collected: quality of life scores (SF-36), 
self-reported adherence (Modiﬁed Morisky scale of 1–5, 1 being always adherent and 
5 being never adherent), number of sick days, and patient satisfaction with services 
(Likert scale of 1–5, 1 being highly unsatisﬁed and 5 being highly satisﬁed). Data was 
analyzed using SPSS v 16.0 for one year using descriptive statistics and Friedman tests. 
RESULTS: One hundred one employees enrolled at baseline. Patients had improved 
scores on physical functioning, role physical, bodily pain, and social functioning. The 
physical component summary remained roughly the same. Mental component scores 
decreased, but not signiﬁcantly. Self-reported adherence improved signiﬁcantly from 
3.83 to 2.68 (p < 0.005) over 12 months. There was a decrease in the use of sick days 
from 1.13 ± 5.32 at baseline to 0.09 ± 0.39(p = 0.368) at the end of the study. Patients 
who reported using sick days at baseline on average reported less use of sick days 
over one year. Overall patient satisfaction signiﬁcantly increased from 3.26 to 4.52 
(p < 0.001) over 12 months. Experience with the pharmacist and experience with 
pharmacy services were the highest rated items. CONCLUSIONS: Improved quality 
of life and adherence can help increase productivity of employees and can help reduce 
costs for employers by reducing disease-related missed days of work. Employers 
looking to save costs and improve productivity can utilize the services provided by 
pharmacists.
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OBJECTIVES: Since pediatric growth disorders such as Growth Hormone Deﬁciency 
(GHD) and Idiopathic Short Stature (ISS) might affect subjective wellbeing and func-
tioning, treatment outcomes should include assessment of quality of life (QoL). The 
multinational QoLISSY project aims at developing simultaneously in 5 countries, a 
targeted instrument to measure outcomes in short stature children in three age groups 
(4–7, 8–12, & 13–18 yrs.). METHODS: The project follows international instrument 
development guidelines and uses focus groups, cognitive interviewing, and pilot- and 
ﬁeld testing. Per country, 24 children (height <−2 SDS) and one of their parents were 
recruited into focus groups according to age group (8–12 and 13–18 yrs.), gender, 
diagnosis (ISS/GHD) and GH-treatment (treated and non-treated). Statements derived 
from focus groups were used to formulate items which were subsequently presented to 
24 child-parent pairs per country for cognitive debrieﬁng. Additional focus groups with 
parents of very young children were also conducted. RESULTS: The focus groups 
included 96 children (age 8–18), 126 parent participants, as well as 38 parents of young 
children (4–7 yrs.). All material was transcribed and relevant passages reduced to state-
ments (1800 child, 2500 adult) which were further reduced to items (170 child, 209 
adult). CONCLUSIONS: This process provided rich material for further analysis and 
a sound basis for pilot testing. Short stature appears to be a main focus of attention for 
children and their parents, with teasing and bullying as frequent experiences. Some 
inter-individual and cross-cultural differences in concepts were found, suggesting a 
more complex model for understanding wellbeing and functioning than ﬁrst envi-
sioned. These preliminary results showed that a comprehensive taxonomy of psycho-
logical outcomes is needed as well as more research regarding the effects of psychological 
and medical treatment on quality of life of short stature children and their families.
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OBJECTIVES: Prior to use in an international study, the PedsQL™ 3.2 Diabetes 
Module consisting of 5 reports (Teen report, Adult report, Child report, Parent report 
for teens, Parent report for children) underwent linguistic validation into 10 languages. 
A rigorous methodology was conducted to ensure conceptual equivalence, cultural 
relevance and appropriateness of formulations across the 3 age categories. This 
involved forward / backward translations and testing on a sample of the 3 age groups. 
29 out of 32 items being identical in the original, the aim of our study was to inves-
tigate if this was the case in the translations, determine a potential pattern should 
there be differences and make recommendations on the basis of the results. METHODS: 
This investigation was carried out as follows: 1) Comparison of the 29 identical items 
across the Teen, Adult and Child reports in the 10 translations; 2) identiﬁcation of 
differences across the three reports; and 3) determination of a pattern in the differ-
ences. RESULTS: First results indicate that language versions are relatively similar 
across the 3 reports with few differences and no identiﬁable pattern. The differing 
formulations across age groups are not the same across translations. Differences are 
not linked to the translation of technical terms, but found in items on general symp-
toms. CONCLUSIONS: The similarities across the 3 age-speciﬁc forms for the 10 
languages seem to indicate the universal and intergenerational acceptability of the 
original concepts and their formulations. Given the differences without identiﬁable 
pattern across age categories in some languages however, it is recommended to test 
the understanding of each item through cognitive debrieﬁng on a sample of each age 
group despite the use of identical formulations in the original. This will ensure appro-
priate comprehension across age groups and translations and facilitate international 
comparison and pooling of data.
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OBJECTIVES: To examine how obesity and quality of life (QOL) affect medical (MC) 
and lost productivity costs (LPC) in U.S. adults with diabetes. METHODS: A cross 
sectional study design was applied using the 2003–2006 Medical Expenditure Panel 
Survey data. The study population consisted of patients aged 18–64 with diabetes, 
but without immunodeﬁciency, malignancy, kidney dialysis, or underweight. Diabetic 
patients’ QOL were classiﬁed as low (≤25%), medium ( > 25%- < 75%), and high 
(≥75%) based on quartiles of the SF-12 physical component scale(PCS-12) and mental 
component scale(MCS-12) respectively. Patients’ BMI was classiﬁed as normal, over-
weight, and obese. Diabetic complications included heart disease, stroke, retinopathy, 
neuropathy, and nephropathy. MCs were estimated using a generalized linear regres-
sion model with log link and gamma distribution after adjusting for patient charac-
teristics and comorbidities. LPC were calculated based on missed working days due 
to illness and average hourly wage using a two part model for working adults. All 
costs were converted to 2008 U.S. dollars. RESULTS: The study identiﬁed 3,621 
diabetic patients. Patients with low PCS-12 had more complications, compared to 
those with high PCS-12 (17.0% vs. 4.4%). A similar trend was also observed for 
MCS-12 (11.8% vs. 8.2%). In general, patients with lower PCS-12 had higher MC 
($12,203 in low-QOL vs. $3,172 in high-QOL) and LPC ($1,632 in low-QOL vs. 
$293 in high-QOL). A similar trend was found in the relationship between MCS-12 
and both costs, but this relationship was weaker than that of PCS-12. Among patients 
with medium to high PCS-12, obese patients had higher MC and LPC than normal 
or overweight patients. CONCLUSIONS: Lower levels of QOL were associated with 
a higher economic burden on diabetic patients, especially the physical QOL compo-
nent. Among diabetic patients with higher levels of physical QOL that are less con-
founded by disease severity and complications, the impact of obesity on economic 
burden was observed.
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OBJECTIVES: The objective of the study was to understand of the impact of diabetes-
related non-severe hypoglycemic episodes (NSHE’s) on work productivity and diabetes 
management. METHODS: A web-based survey was developed based on literature, 
expert input and 68 patients participating in focus-group or individual interviews. 
Persons with self-reported diabetes in US, France, Germany, and UK participated in 
the survey. NSHE’s were classiﬁed as occurring in the past month, either daytime 
(while at work or not at work) or during sleep. RESULTS: A total of 6756 persons 
were surveyed of whom 972 (14.4%) worked for pay and had a NSHE. The mean 
age of the sample was 41.3 ± 13.5. There were no signiﬁcant country differences for 
% on insulin vs. oral or % type1 vs. type 2 subjects. Fifty-nine percent of type 1 
subjects (range 50.7% in France – 70.9% in US, p = 0.001) and 34.8% of type 2 
